February 2015

New Product - Brintellix

Brintellix (vortioxetine (as hydrobromide)) is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist; its mechanism of action is thought to be related to its multimodal activity: direct modulation of receptor activity and inhibition of the serotonin transporter. Brintellix is indicated in the treatment of major depressive disorder in adults including prevention of relapse. Vortioexetine is not indicated for paediatric use. Brintellix should not be used in combination with a MAOI, or within at least 14 days of discontinuing treatment with an MAOI. Brintellix should be discontinued for at least 14 days before starting treatment with a MAOI. Brintellix is available as 5 mg, 10 mg, 15 mg and 20 mg film coated tablets in blister packs of 28’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629